Letter to the Editor Regarding: “Botulinum Toxin A in the Management of Pediatric Sialorrhea: A Systematic Review” Ann Otol Rhinol Laryngol . 2023 Feb 18;doi: 10.1177/00034894221078365

Abstract

View all access options for this article.

Heikel

Patel

Ziai

Shah

Lighthall

JG.

Botulinum Toxin A in the management of pediatric sialorrhea: a systematic review. Ann Otol Rhinol Laryngol. 2023;132(2):200-206.

Page

McKenzie

Bossuyt

, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Xeomin (incobotulinumtoxinA). FDA full prescribing information. Merz Pharmaceuticals Germany; 2021. Accessed January 2023. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/380473

Xeomin (incobotulinumtoxinA). Summary of product characteristics. Merz Pharmaceuticals Germany; 2008. Accessed January 2023. https://www.ema.europa.eu/en/documents/referral/xeomin-article-29-referral-annex-i-ii-iii_en.pdf

Myobloc (rimabotulinumtoxinB). FDA full prescribing information. Solstice Neurosciences, Inc.; 2009. Accessed January 2023. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/381773

Botox (onabotulinumtoxinA). FDA full prescribing information. Allergan Pharmaceutical Ireland; 2022. Accessed January 2023. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/380470

Dysport (abobotulinumtoxinA). FDA full prescribing information. Ipsen Biopharm Limited; 2009. Accessed January 2023. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/380472

Berweck

Bonikowski

Kim

, et al. Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children: SIPEXI. Neurology. 2021;97:1425-1436.